Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Flow Cytometry Employed in Diagnosing Male Urethritis

By LabMedica International staff writers
Posted on 17 Dec 2020
According to the established guidelines, diagnosis of non-gonococcal urethritis should be confirmed by demonstrating polymorphonuclear leukocytes from the anterior urethra using a Gram-stained (GSS) or methylene blue-stained urethral smear.

There are several methods for detecting these infections. More...
In recent years, new technologies have emerged in the field of urinalysis methodology, offering quick and standardized opportunities in everyday clinical practice. However, there is only limited information about how to use flow cytometry in diagnosing male urethritis.

Medical Andrologists and their colleagues at Tartu University Hospital (Tartu, Estonia) recruited 306 male patients with infectious urethritis caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and/or Trichomonas vaginalis. The control group consisted of 192 patients without uro-genital complaints, negative tests for C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis from first-voided urine and no inflammation in first-voided urine, mid-stream urine and urine after prostate massage.

The concentration and total count of white blood cells and bacteria in urine were analyzed using urine flow cytometry. The analyses were performed using fully automated urine particle analyzer Sysmex UF-500i (Sysmex Corporation, Kobe, Japan). Urethritis-associated sexually transmitted infections (STIs were detected from the first-voided urine using a PCR method: C. trachomatis and N. gonorrhoeae DNA by cobas 4800 CT/NG Test (Roche Diagnostics, Risch-Rotkreuz, Switzerland); M. genitalium DNA /Mycoplasma genitalium Real-TM; T. vaginalis DNA by Trichomonas vaginalis Real-TM (Sacace Biotehnologies, Como, Italy).

The investigators reported that the most prevalent infection was chlamydia (64.1%), followed by Mycoplasma genitalium (20.9%), gonorrhoea (7.8%) and trichomoniasis (1.6%). Gonorrhoea caused the highest flow-cytometric leucocyte/bacteria count, followed by chlamydia and Mycoplasma genitalium. Trichomonas vaginalis showed nearly absent inflammation in first-voided urine. Using an empiric flow-cytometry diagnostic threshold for urethritis in first-voided urine (leucocytes ≥ 15/μL and bacteria ≥ 20/μL), the total calculated sensitivity was over 90%. However, when applying such criteria for deciding whether to perform first-voided urine PCR for C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis or not, the team could miss 23 cases with infectious urethritis that makes up 7.5% of all proven cases.

The authors concluded that C. trachomatis (CT) is the most prevalent urethritis-associated STI among the men consulting an andrologist, followed by M. genitalium (MG). A strong inflammatory reaction accompanied by high bacterial concentration in first-voided urine as revealed by flow cytometry is highly predictive of NG infection (sensitivity >95%), while the sensitivity of this method remains slightly lower for CT and MG (>92%) and very low for infrequently occurring T. vaginalis. The study was published on December 2 2020 in the journal PLOS ONE.

Related Links:
Tartu University Hospital
Sysmex Corporation
Roche Diagnostics
Sacace Biotehnologies



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.